

HIGH PRESSURE LIQUID CHROMATOGRAPHIC METHOD FOR SIMULTANEOUS DETERMINATION OF KETOPROFEN AND OMEPRAZOLE

V. Maslarska¹, S. Bozhanov¹, B. Tsvetkova², L. Peikova^{2*}

Medical University – Sofia, Faculty of Pharmacy, ¹Department of Chemistry,

²Department of Pharmaceutical chemistry,

2 Dunav str., 1000 Sofia, Bulgaria

Abstract: A simple, specific, precise and accurate reversed phase liquid chromatographic method has been proposed for the simultaneous determination of ketoprofen and omeprazole in laboratory mixture.

The chromatographic separation was performed on a LiChrosorb C₁₈, 125 mm x 4.6 mm, 5 µm column at a detector wavelength of 230 nm and a flow rate of 1.5 ml/min. The mobile phase was composed of phosphate buffer (pH adjusted to 4.6 with ortho-phosphoric acid) and methanol (25:75 v/v)

The retention times of ketoprofen and omeprazole were found to be 3.05 and 6.96 min, respectively. The method was validated for the parameters like specificity, linearity, precision, accuracy, limit of quantitation and limit of detection. The calibration curves were linear in the concentration range of 25.00-200.0 µg/ml for ketoprofen and 5.00-40.00 µg/ml for omeprazole. The estimated relative standard deviation values of % recovery at accuracy studies were found to be not greater than 3 %.

The presented method for the simultaneous determination of ketoprofen and omeprazole in synthetic mixture is specific, rapid and simple with good sensitivity.

Key words: Ketoprofen, omeprazole, HPLC, validation, laboratory mixture, quality control

Introduction

Omeprazole (OME), chemically is (RS)-5-methoxy-2-[4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulphonyl-1H-benzimidazole. It functions as proton pump inhibitor and used in the treatment of gastro-esophageal reflux disease, duodenal, gastric, esophageal ulceration and Zollinger-Ellison syndrome [1]. Literature survey revealed that OME can be analyzed alone and in combination with other drugs in various

dosage forms and biological fluids. The methods include stability indicating high-performance thin layer chromatography [4], high-performance liquid chromatography [3-5], TLC densitometry [6, 9], UV spectrophotometry [8, 9], capillary electrophoresis [10].

Ketoprofen (KET), chemically is (RS)-2-[3-(benzoyl)phenyl]propanoic acid which is non-steroidal antiinflammatory drug with analgesic, antipyretic effects used in

arthritis, severe toothaches, post-herpetic neuralgia, pain for radiculopathy, joint disorders, dysmenorrheal, menstrual cramps and gout [1]. Literature survey reveals that for KET can be analyzed alone and in combination with other drugs in various dosage forms and biological fluids. It includes separation techniques [11-14], UV spectrophotometry [15, 16] and flowinjection analysis [17].

Combination of NSAID with a H₂-receptor antagonists is beneficial as it suppress gastric acid secretion [18, 19].

The aim of the present study was to develop and validate a HPLC method for the simultaneous determination of ketoprofen and omeprazole in laboratory mixture contained 100 mg KET and 20 mg OME. The method described complied with validation requirements of ICH [20] and could be used for routine quality control of pharmaceutical formulations in ordinary laboratories.

Experimental section

Materials and methods

Chemicals and Reagents

Working standards of ketoprofen RS (purity 100.2 %) and omeprazole RS (purity 99.91 %) were provided by (Sigma-Aldrich). LC-grade methanol and ortho-phosphoric acid were procured from Merck (Germany). All other chemical reagents were of analytical grade.

Instrumentation and chromatographic conditions

Chromatographic separation was performed on modular HPLC system LC-10A Shimadzu (Japan) arranged with a LC-10A pump, solvent degasser DGU-3A, Rheodyne injector, column oven CTO-10A, SPD-M10A diode array detector and communication bus module CBM-10A. Separation was achieved isocratically with a LiChrosorb C₁₈, 125 mm x 4.6 mm, 5 µm column eluted with a mixture of phosphate buffer (pH adjusted to 4.6 with ortho-phosphoric acid) and methanol (25:75v/v) as the mobile phase at flow rate of 1.5 ml/min. Detection was carried out by absorbance at 230 nm. The analysis was carried out at an ambient temperature and injection volume was 20 µl.

Preparation of standard solutions

For ketoprofen: 50 mg of ketoprofen was accurately weighed and transferred to a 50 ml volumetric flask and volume was made up to 50 ml with methanol (Stock solution A-1000 µg/ml).

For omeprazole: 20 mg of omeprazole was accurately weighed and transferred to a 100 ml volumetric flask and volume was made up to 100 ml with methanol (Stock solution B-200 µg/ml).

For mixed standard: From the stock solutions A and B dilutions of different concentration were made as mentioned in the Table 1.

Table 1. Preparation of mixed standards

| Stock solution → Volume taken (ml) | | Total volume (ml) | Concentration in µg/ml | |
|------------------------------------|----|-------------------|------------------------|-----|
| A | B | | KET | OME |
| 5 | 5 | 200 | 25 | 5 |
| 5 | 5 | 100 | 50 | 10 |
| 5 | 5 | 50 | 100 | 20 |
| 15 | 15 | 100 | 150 | 30 |
| 10 | 10 | 50 | 200 | 40 |

Preparation of synthetic mixture

A bulk mixture of both drugs was prepared using 100 mg of KET and 20 mg of OME. Common excipients which are used in tablet formulation were added in this laboratory mixture, triturated well and weighed. A powder equivalent to 50 mg of KET and 10 mg of OME was weighed accurately and transferred to 100 ml of volumetric flask, dissolved in sufficient quantity of methanol and volume was adjusted up to the mark with methanol. The stock solution was filtered through a 0.45 μm Nylon syringe filter and 5.0 ml of the filtrate was diluted into a 25.0 ml volumetric flask to give a test solution containing 100 $\mu\text{g/ml}$ KET and 20.00 $\mu\text{g/ml}$ OME.

Results and discussion

The proposed method was validated with

respect to selectivity, linearity, precision, accuracy, limit of quantitation (LOQ) and limit of detection (LOD) according to ICH requirements to show it could be used for simultaneous determination of ketoprofen and omeprazole in laboratory mixture.

Selectivity

From the chromatogram shown in Fig. 1, it is evident, that under the chosen chromatographic conditions ketoprofen ($T_r=3.05$ min) and omeprazole ($T_r=6.96$ min) were completely separated. The specificity of the proposed method was confirmed by injecting blank sample. The specificity analysis revealed the HPLC method did not suffer interference by the formulation excipients, since there were not another peaks on the retention times of ketoprofen and omeprazole.




Figure1. Chromatogram from analysis of sample

Linearity

Calibration curves were constructed in the range of 25.00-200.0 $\mu\text{g/ml}$ for KET and 5.00-40.0 $\mu\text{g/ml}$ for OME to encompass the

expected concentration in measured samples. An excellent correlation existed between the peak areas and the concentrations of both compounds as can be seen from correlation coefficients. The

limit of quantitation and limit of detection were calculated from the standard deviations and slopes of the responses using a signal-to-noise

ratio as per ICH guidelines. Data concerning linearity and sensitivity of the method were shown in Table 2.

Table 2. Linearity data

| Parameter | ketoprofen | omeprazole |
|---------------------------|-------------------|-----------------|
| Linearity range | 25.00-200.0 µg/ml | 5.00-40.0 µg/ml |
| Slope | 13654 | 21452 |
| Intercept | -1098 | 1017 |
| Regression coefficient | 0.9999 | 0.9998 |
| Limit of quantitation, ng | 8 | 12 |
| Limit of detection, ng | 4 | 5 |

Accuracy

The accuracy of the method was determined by calculating the recoveries of KET and OME by the standard addition method. Known amounts of standard solutions of both KET and OME (50, 100, and 150%) were added to

prequantified sample solutions of drug formulation. The method was found to be accurate with recoveries of 98.33%–99.85% and an acceptable RSD of not more than 3% at each level. The recoveries obtained by the proposed method for KET and OME were shown in Table 3.

Table 3. Results from study of accuracy

| Amount of sample (µg/ml) | | Sets | Amount drug of spiked (µg/ml) | | Average amount recovered (µg/ml) | | Mean recovery (%) ± SD | | % RSD | |
|--------------------------|-----|------|-------------------------------|-----|----------------------------------|-------|------------------------|------------|-------|------|
| KET | OME | | KET | OME | KET | OME | KET | OME | KET | OME |
| 50 | 10 | 1 | 0 | 0 | | | | | | |
| 50 | 10 | 2 | 0 | 0 | 49.85 | 9.81 | 99.48±1.15 | 98.77±1.80 | 1.15 | 1.82 |
| 50 | 10 | 3 | 0 | 0 | | | | | | |
| 50 | 10 | 1 | 25 | 5 | | | | | | |
| 50 | 10 | 2 | 25 | 5 | 74.82 | 14.87 | 99.81±0.57 | 99.55±2.54 | 0.57 | 2.55 |
| 50 | 10 | 3 | 25 | 5 | | | | | | |
| 50 | 10 | 1 | 50 | 10 | | | | | | |
| 50 | 10 | 2 | 50 | 10 | 99.74 | 19.57 | 99.75±0.90 | 98.28±2.14 | 0.87 | 2.18 |
| 50 | 10 | 3 | 50 | 10 | | | | | | |

| | | | | | | | | | | |
|----|----|---|----|----|-------|-------|------------|------------|------|------|
| 50 | 10 | 1 | 75 | 15 | | | | | | |
| 50 | 10 | 2 | 75 | 15 | 125.1 | 24.80 | 99.85±0.68 | 99.64±1.40 | 0.68 | 1.40 |
| 50 | 10 | 3 | 75 | 15 | | | | | | |

Precision

Precision is determined by studying the repeatability and intermediate precision. Repeatability (interday precision) result indicates the precision under the same operating conditions over a short interval of time. Intermediate preci-

sion study expresses within laboratory variation in different days. In both inter- and intraday precision study the values of % RSD were not more than 2.0% indicates good repeatability and intermediate precision (Table 4).

Table 4. Precision of the method

| Drug | Interday precision | | Intraday precision | |
|------|---------------------|-------|---------------------|-------|
| | % Amount found± SD* | % RSD | % Amount found± SD* | % RSD |
| KET | 99.52±0.56 | 0.56 | 100.4±0.47 | 0.47 |
| OME | 98.93±0.69 | 0.70 | 99.21±0.39 | 0.39 |

*Average of six determinations

Conclusion

The newly developed RP-LC method for simultaneous determination of ketoprofen and omeprazole in laboratory mixture is specific, precise, accurate and rapid. Hence the proposed method is suitable for the quality control of the raw materials, formulations and dissolution studies.

References

1. Tripathi KD. 'Omeprazole' Essentials of Medical Pharmacology, 5th Edition, 2003; 591-592.
2. Jha P, Parveen R, Khan SA, Alam O, Ahmad S. Journal of AOAC International 2010; 93(3): 787-791.
3. Nahar K, Jafreen JJ, Ashik U, Ahasanul H, Mohammad A, AbulHasnat A. Journal of Pharmaceutical Sciences 2009; 8(2): 123-130.
4. Topagi KS, Jeswani M, Sinha PK, Damle MC, Asian Journal of Pharmaceutical and Clinical Research 2010; 3(1):20-24.
5. Kothapalli LP, Thomas AB, Hurne VA, Bhujbal AB, Nanda RK, Deshpande AD, Inventi Rapid 2011; 3 (2): 152-160.
6. Agbaba D, Novovic D, Karljiković R, Rajić K, Marinković V, International Journal of PharmTech Research 2014; 17(3): 169-172.
7. Patel B, Patel M, Patel J, Suhagia B, Journal of Liquid Chromatography and Related Technologies 2007; 30(12): 1749-1762.
8. Lobhe GA, Banerjee SK, Shirkhedkar AA, Surana SJ, International Journal of Research in Pharmacy and Chemistry 2011; 1(3): 408-411.
9. Kumaraswamy D, Stephenrathinaraj B, Rajveer CH, Sudharshini S, Shrestha B, Rajasridhar Rao P. International Journal of Pharma and Bio Sciences 2010; 1(2): 1-6.
10. Berzas JJ, Castanda G, Analytica-Chimica Acta 2005; 533: 127-32.
11. Baeyens W, Van der Weken G, Hausstraete J, Aboul-Enein HY, Corveleyn S, Remon JP, Garcõa-Campan AM, Deprez P. Biomedical Chromatography 1999; 13: 450-454.

12. Hassib ST, Mohammad AM, Asmaa A. EL-Zaher, Ehab F. EL-Kady. *Journal of AOAC International* 2007; 90 (3): 693-699.
13. Valliappan K, Kannan K, Sivakumar T, Manavalan R, *Journal of Applied Biomedicine* 2006; 4 (1): 153-161.
14. Parimoo P, Bharathi A, Leela P, *Indian Journal of Pharmaceutical Sciences* 1995; 57 (1): 31-34.
15. Wankhede SB, Zambare SS, Chitlange SS, *Journal of Pharmacy Research* 2010; 3(4): 707-710.
16. Pomykalski A, Hanna HA, *Acta Polonae Pharmaceutica Drug Research* 2005; 62 (3):171-176.
17. Aboul-Enein HY, Dal AG, Muzaffer T. *Farmaco* 2003, 58 (1): 419-422.
18. Humphries TJ, Merritt GJ. *Alimentary Pharmacology and Therapeutics* 1999;13Suppl 3, 18-26.
19. Ketoprofen / Omeprazole, 100mg / 20mg, 200mg / 20mg modified release capsules (AxoridÒ), Scottish Medicines Consortium, No.606/10 (2010) 1-7.
20. ICH Harmonised Tripartite Guidelines. *Validation of Analytical Procedures, Text and Methodology, Q2 (R1)*, Geneva, November 2005.

Corresponding author's contacts:

E-mail: lily_peikova@yahoo.com

Mob. Tel: +3590898454851

Tel: +3599236538

Fax: +3599879874
